Opioid abuse is currently the most significant public health problem in the US. Many US states implemented prescription drug monitoring programs (PDMPs) in response.
Introduction
Prescription drug abuse has been described by the Centers for Disease Control as an epidemic in the United States. The rate of drug overdose deaths in the United States in 2015 was more than 2.5 times the rate in 1999, with the greatest percentage increase among adults aged 55-64 (from 4.2 per 100,000 in 1999 to 21.8 in 2015) (Hedegaard et al. (2017) ).
Based on the National Survey of Drug Use and Health, nearly all prescription drugs involved in overdoses are originally prescribed by a physician, rather than, for example, being stolen from pharmacies. Thus, policy makers are increasingly focusing attention on preventing the over-prescription of drugs and their subsequent diversion to people other than the patient.
The main policy response to this prescription drug epidemic is the introduction of Prescription Drug Monitoring Programs (PDMPs), which are in place in all states as of 2017.
As part of these programs, statewide electronic databases have been set up to track prescriptions dispensed for controlled substances. Information collected can be used to identify diverted drugs as well as to facilitate the identification of prescription drug-addicted individuals (Finklea et al. (2014) ). There are a variety of studies examining the effectiveness of PDMPs as implemented in different states. Haegerich et al. (2014) Finally, I study the effectiveness of the program in changing the patterns of prescriptions among providers and the overall probability of taking opioids in the study population. In this section, I perform an analysis similar to Buchmueller and Carey (2017) and Kilby (2016) and compare the results of my study to that of the latest studies conducted on different population groups including Medicare and employer-sponsored individuals .
The Clinformatics Data Mart dataset includes individuals from diverse backgrounds representative of the U.S. population, which enables me to generalize my results to the entire U.S. population. Also, the large sample sizes allow for rich subgroup analysis. Another difference between my study and previous studies is the long time span of data coverage, which makes it possible to test the difference-in-difference assumption of parallel trends and to only include comparison group states that are similar to states that implemented PDMPs. Finally, as individuals' access to prescription drugs also depends to a large extent on their health insurance policies, having detailed information about insurance providers gives me the opportunity to study one of the factors that has not been considered in previous research.
Another novel feature of my analysis is to use the medical claims data as a basis for understanding the problem of drug diversion. Some studies only include people observed to have at least one opioid prescription, but my results show that, among the abuser population, at least 23% did not fill any opioid prescriptions during the year of treatment. My results show that there is not necessarily a close correspondence between dose of medication prescribed and propensity for abuse.
My results show an overall 14% percent reduction in odds of abuse/addiction.The effect is slightly higher for females compare with males, and for blacks compare with whites.
The effect is seen most clearly in the low-income population and also in highly educated people. PDMPs decreased the odds of abuse by 17% among low-income families, 12% for middle income families; there was no significant effect for higher income families. These programs also decreased the odds of abuse by 16% among bachelor degree holders, while no significant effect was evident for people with less than a high school education. PDMPs effectiveness varies significantly by type of insurance, the odds of abuse reduced by 19% for those with HMOs, 11% for those with EPOs and no significant effect for those with PPOs or POS plans. This is intuitive given that insurance policies lead to different patientprovider matches due to in-network and out-of-network provisions. I can see that, although PDMPs provide similar information to all providers, the insurance structure matters for the effectiveness of these programs for each demographic subgroup analyzed. A caveat is that it could be possible that people having an opioid abuse problem would choose insurances that are more generous and more lenient when it comes to getting access to providers that give prescriptions.
Prescription claim histories show that at least 23% of opioid abusers do not have any insurance claims for opioid purchases, which means at least 23% of abuse/addiction cases are the result of opioid diversion. There is no significant effect from PDMPs in abuse/addiction reduction among individuals without opioid prescription claims. Finally, PDMPs have affected other outcomes, including the number of pharmacies and providers visited by patients and quantities of prescribed medications. 4 2 Background
Opioid for pain management
Opium has been used for pain management for centuries. The opioid family of drugs continues to be a major part of pain management in medical practice today (Ballantyne and Mao (2003) ). Despite its pervasive use, there is little certainty on opioid therapy's risks and benefits.
The first opioid epidemic occurred in the late 19th century, which resulted in the first legal attempts to restrict access to these drugs. In addition to these legal attempts, the introduction of other pain medications limited the use of opioids.
In the late 1980s, however, there was a shift in the discussion of chronic noncancer pain management. Portenoy and Foley (1986) studied 38 cases of long-term opioid therapy, asserting that it was a "humane alternative" to other forms of pain management (e.g. surgery). Similarly, Zenz et al. (1992) observed 100 patients taking opioid therapy lasting 224 days on average and found no cases of addiction. They thus declared opioid therapy as an effective treatment for long-term pain management without addiction being an important concern. Papers with similar conclusions emerged in subsequent medical literature (Fink (2000) , Portenoy (1996) ). On the ground, the introduction of OxyContin in 1995 shifted the treatment of pain drastically. Purdo Pharma funded more than 20,000 pain-related educational programs to alter physicians' and medical professionals' perceptions of opioid therapy. Although there were no clinical trials to assess the safety of long-term opioid treatment for noncancer patients, the company cited some methodologically flawed papers claiming that the risk of addiction was as low as 1% (Kolodny et al. (2015) ). By 1998, "[k] ey organizations that strongly support[ed] the use of opioids to treat chronic pain [...] published consensus statements to guide physicians in prescribing these drugs" (Ballantyne and Mao (2003) ).
With these developments, in 1996, the rate of opioid use started to increase. This was followed by an increase in the rate of mortality and morbidity by opioids, but it took policy makers some time to realize that it was not only the nonmedical users who were at risk of overdose. Pain patients who were addicted to opioids were a group that was very likely to overdose on these drugs (Kolodny et al. (2015) ). Furlan et al. (2006) , in a meta-analysis of opioid therapy studies, inferred that, despite common belief, "[a]ddiction or opioid abuse in patients with chronic pain cannot be assumed not to exist" because the length of trials are too short for development of addictive behaviors. Martell et al. (2007) investigated the case of patients with chronic back pain and found that, although the effectiveness of these drugs for long-term pain management was unclear, abusive behavior developed in around 25% of the patients. Another review by Højsted and Sjøgren (2007) suggested that the risk of addiction could be as high as 50% in noncancer pain patients. Furthermore, Dunn et al. (2010) investigated the relationship between prescribed doses of opioids and abusive behavior and concluded that "[p]atients receiving higher doses of prescribed opioids are at increased risk of opioid overdose, underscoring the need for close supervision of these patients."
In response to this growing public health risk, policy makers first targeted illegal access, but as inappropriate use among patients became more clear by 2005, different policies focusing on this segment emerged. The Prescription Drug Monitoring Programs, which are described in the following section, are the most important of these policies.
Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) are state-administered databases that contain information on the prescribing and dispensing of controlled substances. Information contained in the PDMPs may be used by doctors and pharmacists to identify patients who may be doctor shopping (seeing multiple doctors to obtain prescriptions), need substance abuse treatment, or are at risk for overdose. In accordance with state laws, PDMP information may also be used by state regulatory and law enforcement officials to pursue cases involving inappropriate prescribing or dispensing, so-called "pill mills," or other sources of diversion.
The first PDMP was established in California in 1939, and as the need to collect data on prescription drugs for law enforcement and monitoring purposes grew, 8 more states established this program by 1989. In this period, which is called the "Paper Era" of the PDMPs, the information was mainly used by law enforcement agencies to curtail diversion.
By 1990, the "Electronic Era" of the PDMPs began, which made the sharing of data easier between providers, pharmacists and drug agencies. In the next decade, the steady rise in the abuse and diversion of controlled substances further increased the importance of PDMPs, and eventually there was a drive to align and consolidate the programs in different states, which so far differed vastly in regulations and implementation. Thus started the "Federal Era" of the PDMPs in 2002, when the the National Alliance for Model State Drug Laws (NAMSDL) drafted a model program outlining common goals that should be shared among existing and new PDMPs (Blumenschein et al. (2010) ). As a result, PDMPs that were enacted in states after 2003 were very similar, and their enactment can be viewed as a natural experiment in contrast to the early PDMPs that were started in states with high abuse rates.
The impact of PDMPs has been studied in three main areas: effects on provider behavior, patient behavior and health outcomes. PDMPs resulted in a decrease in the number of prescriptions for schedule II narcotics such as oxycodone but resulted in an increase in prescriptions for schedule III pain killers such as hydrocodone, which are easier to prescribe. Overal, however these programs decreased inappropriate prescription behaviors. NAMSDL reflects the date that prescribers and/or dispensers were allowed to have access to PDMP information, whether electronic or hard copy, while TTAC's category reflects the date that the programs began receiving and storing data electronically. 4 Table 1 reports the implementation date provided by NAMSDL. 5 In addition, I use the Prescription Drug Abuse Policy System, which provides detailed data of variation in state laws regarding implementation of PDMPs up to 2016 using the relevant legislative documentations to examine the similarities and disparities among the states in my study. 6 States that I include in my analysis provide access to prescribers, dispensers and the regulatory board. Dispensers have to report data to PDMPs; however, access to PDMPs before prescribing is not mandatory, and PDMPs are not allowed to share the data with private insurers. PDMPs differ in their permission or requirement to identify suspicious activity and take any action, such as reporting suspicious activities to law enforcement or provider/dispenser. By restricting the data to these 25 states, and people 11 to 65 years of age, my final sample includes around 6 million people annually for approximately 19 million unique individuals.
Trends in prescription drug abuse/dependence, co-occurrence with other substance use disorders
There have been some controversies about the underlying factors for opioid abuse or dependence, as these drugs differ from other street drugs in that they are the only ones that can be accessed for legitimate medical reasons but lead to dependence. At first, policy makers assumed that abuse or dependence on these products occurs only among people who do not have a medical prescription for opioids; however, they later found that there is such a thing as accidental dependence. The possibility of opioid abuse/dependence among medical users shifted the focus of drug control from solely the distribution level to the patient level as well.
Incidence of abuse/dependence among pain patients suggests that long-term opioid therapy may lead to dependence and abuse. At the same time, nonmedical abuse is also prevalent. Surveys show that the main source for nonmedical use of opioids is prescriptions written for friends or family members, which suggest over-prescription of these drugs.
Understanding the inherent differences between these two groups of people, medical and nonmedical users, is important for effective policy making.
Surveys on nonmedical users of opioids suggest that these people are also more likely to abuse other drugs (McCabe et al. (2008) ); therefore, studying the demographics of abusers with multiple substance problems, in combination with their medical history, should provide a picture of these types of abusers and how they differ from patients on opioid therapy who ended up as abusers. At first, I look at the trend of abuse or dependence for different substances. I identify substance abuse, addiction or poisoning by applying the ICD-9 7 codes listed in Table 2 to the five provided diagnoses codes in each medical record. Descriptions associated with each ICD-9 code are provided in the documentation for the CDM data.
8 Similar diagnoses in a given day, or as part of one insurance claim, counts as one visit. The total cases of substance abuse/dependence more than doubled during these 10 years, but the growth has been fastest for the opioid drug family. The total number of admissions in this group more than quadrupled. Further, the rates and trends in admissions by each cause, especially for alcohol and opioids, are similar to those reported by SAMHSA (2014b), which confirms that this dataset closely represents the United States population. Table 3 shows that more than 99% of opioids reported in cases of abuse/dependence are prescription opioids. The share of these drugs is constantly increasing, while percentage of heroin-related cases decreased from 0.53% to 0.36%, and methadone-related cases decreased from 0.29% to 0.09%. 9
The studies based on the treatment admission data without specific individual identifiers may provide biased information about the characteristics of the population under study. I estimate the average number of visits for each type of drug abuse/dependence by dividing the total number of visits in each category by the total number of unique individuals in each one. Table 4 shows these multiple visits during a year are common for all type of substances. A person with an opioid abuse or dependence problem on average visits inpatient or outpatient facilities seven times a year. So instead of studying the pop-7 International Classification of Diseases, Ninth Revision. 8 I use ICD-9 codes provided by the Centers for Disease Control and Prevention to identify poisoning cases: https://www.cdc.gov/drugoverdose/pdf/pdo guide to icd9cm and icd10 codesa.pdf; I use the description provided for each code to identify the cases of addiction for each substance. My list is similar to other studies with slight differences; for example, Meara et al. (2016) use similar codes to identify nonfatal opioid-related abuse cases, but they also include E950.0, which is associated with suicide. In addiction to that, my list includes dependence to opioid cases. Table 5 shows that there is a high correlation between the abuse of different types of substances with the highest being 0.35 for the correlation between opioid and other medications abuse. The correlation between abuse of opioids and other substances including cocaine, cannabis and amphetamines is 0.18, 0.14 and 0.10, respectively. For the rest of the data summary, I focus on individuals with a prescription opioid abuse/dependence history. Table 6 shows that people who visit medical providers for only opioid misuse are on average 3.5 years older than people who get admitted for a combination of drugs, including opioids. this provides some suggestive evidence that the older population uses opioids for medical reasons rather than for recreational purposes. Figure 3 shows the percentage of the people abusing opioids in each age group during 2001-2012. The probability of abuse is almost the same, 0.1%, among those 18-54 years of age in 2001, but it is increasing with a different rate among different age groups. The probability goes to 0.79% for those 18-23 years of age (620% rate of growth) and 0.55% for those 24-33 years of age (399% rate of growth). The rate of growth is drastic among the elderly as well, it goes from 0.06% to 0.26% (376% increase).
Providers prescribe opioids differently for different demographics based on age, gender and income or race/ethnicity. Pletcher et al. (2008) argue that white people are more likely to get opioids for pain-related admissions to emergency rooms in comparison with other races, and even the "national quality improvement initiatives" of the 1990s did not reduce this gap. PDMPs aim to provide information about the medical history of patients to improve the practice of prescribing controlled drugs, but it is not clear how these programs affect the already existing biases. I will investigate this using regression analysis in the next section.
4 Econometric Analysis 4.1 Effect of PDMPs on prescription opioid and heroin abuse/dependence I first consider the effect of PDMP implementation on the abuse/dependence of prescription opioids and heroin in the whole population. I estimate the following regression models:
(1)
Here, y it is an indicator for patient i abusing either heroin or prescription opioids in year t, γ i is the individual fixed effect, λ t is the time fixed effect, pdmp st is an indicator for active PDMP in state s during year t and pdmp s,t+l is an indicator for active PDMP in year t + l. The event study analysis in the second equation is necessary to test the validity of the parallel trend assumption in difference-in-difference analysis, it confirms that the implementation of PDMPs for the set of states included in my analysis qualifies as a natural experiment. Figure 4 shows the estimation results of equation 2. It is clear that after controlling for individual and year fixed effects, there is no significant trend in the abuse of prescription opioids or heroin before implementation of PDMPs among states included in my data. Figure 4 shows that the implementation of PDMPs reduced the probability of prescription drug abuse/dependence but gradually increased the probability of heroin abuse/dependence. The increase becomes significant two years after the program.
Effect of PDMPs on prescription opioid abuse/dependence in subsamples
In this section, I study the individual characteristics that determine the effectiveness of the programs in reducing prescription opioid abuse/dependence for each sub-sample. I first estimate the model including individual characteristics and the interaction between characteristics and PDMP implementation instead of individual fixed effects:
In which X it is a vector including age, gender, race, income, education and type of insurance.
I use the logistic regression in order to accommodate the smaller sample size in some of the subgroups. In Table 7 
X it includes all individual characteristics not used in categorizing people in sub-samples.
Although the type of insurance seems to be an endogenous variable, it is unlikely that it will be affected by the event of abuse or addiction. In Table 9 , I show that the effectiveness of the program decreases by family income even after controlling for education level. The odds of opioid abuse decreases by around 18% for individuals from low-income families (less than $40,000), 10 to 13% for individuals from middle-income families ($40,000-$75,000), while having no significant effect for people from higher-income families. Table 10 shows that the effectiveness increases by individuals' education level; people with a higher education are less likely to abuse prescription opioids after implementation of PDMPs. The reduction in the odds ratio is the highest for those with bachelor degrees (17%). PDMPs subsequently decrease the odds ratio of those with bachelor degree by 16% and those with high-school diploma with 11%. It is important to notice that these effects are estimated after controlling for family income level, age and gender, which suggest one mechanism for effectiveness of these programs is informing individuals about the risks of opioid use. Table 11 reports the results by the type of insurance. It suggests that HMO insurance holders benefit the most from PDMPs, followed by those with EPOs. PDMPs resulted in a 20% reduction of the odds of abuse for those with HMOs, a 12% reduction for those with EPOs and no significant effect for people with PPOs or POSs. This is intuitive given that insurance policies lead to different patient-provider matches due to in-network and out-of-network provisions. I can see that, although PDMPs provide similar information to all providers, the insurance structure matters for the effectiveness of PDMPs for each demographic subgroup analyzed. A caveat is that it could be possible that people who have an opioid abuse problem would choose insurances that are more generous and more lenient when it comes to getting access to providers that give prescriptions.
Relationship between the abuse/dependence and prescription
The next step in analyzing the abuse/dependence of prescription opioids is to understand the relationship between abuse and prescriptions for opioids. To investigate the relationship between abuse and prescription, I assign an indicator rx = 1 to each individual-year if a person has an opioid prescription filled during that year. I identify narcotic in prescription claims data by using universal standard classification codes (usc-id) provided by the CDM for each drug. '022**' is the usc-id code for any form of narcotics, tablet, capsule, patch, etc. at any strength, including less controlled and more easily prescribed narcotics such as acetaminophen-codeine. There are hundreds of different opioids in the data with highest frequency being for Oxycodone, hydrocodone, codeine and propoxyphene. To have a valid measure to compare different prescriptions over time, I use the morphine equivalent of each prescription by multiplying the quantity of the drug being prescribed by the milligram morphine equivalent (mme) factor for each drug and then aggregating the data for each individual for each year to find the total mme of prescribed medication. In addition, I find the total days of supply, the number of distinct pharmacies and the providers that each patient visited to get prescriptions for opioids which I will use in the next section. Then, I combine medical history with prescription claims data to investigate the effects of being prescribed any type of narcotics in opioid abuse/dependence.
Information from I include all the prescriptions filled for any type of narcotics at any dose and quantity.
The morphine content of some prescriptions is very small, which makes it impossible to cause any sort of abuse or addiction. In Table 5 , I look at the population that ever been prescribed any narcotics and the population of abusers separately throughout the years from 2001 to 2012. In the sample of people who have abused opioids in each year, around 37% had not been prescribed any opioids in 2001, and this number increased throughout the years, which means that abuse of narcotics without prescriptions prevails over these years. These numbers are just a rough estimate since patients could save prescriptions in a given year and abuse them in the future. But as we saw in Table 12 , even after pooling the data over the years, the number of abusers/addicts with no prescriptions is at least as high as 23%, so the actual number may be somewhere in between. In the sub-sample of people who received opioid medication, 0.49% abused opioids in 2001, and this number constantly increased and reached 1.25% in 2012. As we saw in Table 12 even if we include all the prescription claims throughout the coverage, only 1% of total individuals filling a prescription ended up abusing it themselves.
Although different surveys show that friends and family are the main sources of opioids among nonmedical users (McCabe et al. (2007) ), it is not possible to find the source of these drugs in my data. It is only possible to study the demographic of this population to provide a more accurate guideline for providers. In Figure 6 , it is clear that the distribution of the age of nonmedical abusers is tilted to the left, suggesting that the younger population uses these drugs for recreational purposes, especially people younger than 24 years of age. On the other hand, among those 54-64 years of age, it is twice as likely for abusers to be getting the drugs through prescription rather than other sources. I similarly look at the patterns by other demographics. Although not as clear as in the case of age, it seems that whites and females who abuse opioids are more likely to get them through prescriptions. I estimate the effectiveness of PDMPs in preventing diversion by estimating a regression model similar to that of the previous section for two groups of people-those who filled any prescription for opioids and those who have not:
X it includes total mme and days of supply of medication for people who filled any prescription for opioids. Table 13 shows that, after controlling for mme and days of supply, implementation of PDMPs reduced the odds of opioid abuse by 10% among patients, but they did not have any significant effect on the abuse of opioids among nonmedical users.
One of the goals of PDMPs was to reduce the diversion of opioids by restricting the access to these drugs among patients, but my results suggest that these programs did not provide any benefit of this sort.
Patterns of opioid prescription
One of the more studied aspects of PDMPs is the study of the effect they have in the patterns of prescriptions. I perform a series of analyses similar to Kilby (2016) and Buchmueller and Carey (2017) . I estimate the model:
In which y it measures total mme for each patient i at year t. The results in Table 16 show a reduction in prescribed opioids similar to the finding in Kilby (2016) from analyzing Automated Reports and Consolidated Orders System (ARCOS) data. But non of the specifications resulted in a significant estimation.
I follow the Buchmueller and Carey (2017) in constructing some proxy measures of misuse consisting of quantity-based outcomes and shopping outcomes. The first measure is the share of enrollees that took any opioids at all. The other quantity-based outcomes are intended to capture patterns that are indicative of misuse or dangerous for individuals'
health. It includes an indicator for higher than 391 days of supply in year (more than thirteen thirty-day prescription), having a daily average of opioid use higher than 120 milligram morphine equivalent (mme). The shopping outcomes include indicator for patients who visited more than 10 prescribers in a year to get prescription for opioids and more than 10 pharmacies to fill their prescriptions for opioids. I report the summary statistics of these variables in Table 14 . To evaluate the PDMP effect on these variables, I use the aggregate level difference in difference analysis:
Here, y st in the frequency of outcome in each state year divided by the total number of population with at least one prescription for opioid. γ s and λ t represent state and year fixed effects and standard errors clustered at state level. I weighted each observation with value of denominator. I report the results of these estimations in Table 17 . These results can be compared with the results of Buchmueller and Carey (2017) for the states without the "must access" PDMP requirement. Buchmueller and Carey (2017) do not find any significant effect for similar variables and conclude that without the "must access" specification PDMPs are not effective. My estimation shows that PDMPs effectively reduce the cases of +391 days of supply among prescription holders. The rate of visiting more than 10 pharmacies decreased by 0.034%. Similar to the individual level analysis in previous section, the rate of opioid abuse significantly decreases among people with prescriptions.
The discrepancy among the results of the two studies are likely to be the results of the difference between sthe ubsample population in each study. Buchmueller and Carey (2017) study the Medicare part D beneficiaries while my analysis represents the whole population, which means that PDMPs are more effective in reducing opioid misuse among the general population in comparison toreducing opioid misuse among Medicare part D beneficiaries.
Limitation
There are limitations that arise from the use of the ICD-9 codes in identifying abusers, similar are mentioned in other studies that use this method (White et al. (2009) ). This way of identification is likely to underestimate the number of cases for two reasons. Individuals experiencing nonfatal overdoses also might be less likely to seek care because they expect disapproval or legal consequences (Paulozzi (2012) ). Also, if patients don't use insurance for payment of medical treatment, I won't be able to observe them in this dataset.
Conclusion
Despite the strong emphasis of the role of Prescription Drug Monitoring Programs on the war on prescription drug abuse, there has not been much conclusive evidence in the literature that these programs actually reduce the abuse of these drugs. In this study, I analyze opioid addiction in addition to opioid poisoning to measure the health benefits of the PDMPs.
Using a nationally representative dataset, including 25 states from 2001-2012, I show that
PDMPs have been effective in reducing the probability of abuse/addiction of opioids. The effect is heterogeneous among different groups based on their income, education and ethnicity, but more importantly, the effect is heterogeneous for people holding different insurance policies. This suggests that some practices among HMO insurance providers, including a close network of providers and referral requirements for visits to specialists, may prove to be valuable when it comes to fighting the opioid abuse epidemic. Meara et al. (2016) and Buchmueller and Carey (2017) . Notes: Cases of methadone abuse/dependence are identified with ICD-9 codes different from other prescription opioids as reported in Table 2 . For the rest of the analysis, I consider Methadone as part of prescription opioid cases. 
( 1 Notes: Coefficients of logit regression for probability of an individual diagnosed with abuse/addiction of prescription opioid. Individual controls include age, gender, education, income and type of insurance. Robust standard errors, clustered at the state level are in parentheses. * p <0.10, ** p < 0.05, *** p <0.01 Table 9 : Effect of PDMP on probability of abuse by income category Notes: Coefficients of logit regression for probability of an individual diagnosed with abuse or addiction of prescription opioid for different income groups. Individual controls include age, education, gender, type of insurance. Robust standard errors, clustered at the state level are in parentheses. * p <0.10, ** p < 0.05, *** p <0.01 Table 10 : PDMP effect on probability of abuse by education level Notes: Coefficients of logit regression for probability of an individual diagnosed with abuse or addiction of prescription opioid for different education level. All specifications control for other individual characteristics including age, gender, income and type of insurance in addition to state and year fixed effects. Robust standard errors, clustered at the state level are in parentheses. * p <0.10, ** p < 0.05, *** p <0.01 6,931,178 16,550,381 159,186 34,051,197 4,888,403 Notes: Coefficients of logit regression for probability of an individual diagnosed with abuse or addiction of prescription opioid for different insurance. All specifications control for individual characteristics including age, gender, income and education in addition to state and year fixed effects. Robust standard errors, clustered at the state level, in parentheses. * p <0.10, ** p <0.05, *** p<0.01 Notes: Summary statistics of misuse proxy measures, constructed similar to Buchmueller and Carey (2017) . 
(1) 391+ Days Supply 1 (2) 120+ Daily MME 0. Notes: The dependent variable in (1) is the total mme in each year for each individual. The dependent variable in (2) is the log transformation of the mme+1. The dependent variable is (3) is schedule 2 share of total mme, the dependent variable in (4)is the log transformation of schedule 2 mme+1. Similarly, dependent variables in (4) and (5) are the schedule 3 mme and its log transformation.
Robust standard errors, clustered at the state level are in parentheses. * p <0.10, ** p < 0.05, *** p <0.01 Notes: Dependent variables are constructed similar to Buchmueller and Carey (2017 
